{"id":"NCT01178073","sponsor":"GlaxoSmithKline","briefTitle":"A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)","officialTitle":"AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-10-01","primaryCompletion":"2014-07-31","completion":"2014-07-31","firstPosted":"2010-08-09","resultsPosted":"2015-04-28","lastUpdate":"2017-09-13"},"enrollment":610,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypertension, Pulmonary"],"interventions":[{"type":"DRUG","name":"ambrisentan","otherNames":[]},{"type":"DRUG","name":"tadalafil","otherNames":[]}],"arms":[{"label":"Combination ambrisentan + tadalafil","type":"ACTIVE_COMPARATOR"},{"label":"Monotherapy ambrisentan","type":"ACTIVE_COMPARATOR"},{"label":"Monotherapy tadalafil","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the two treatment strategies; first-line combination therapy (ambrisentan and tadalafil) versus first-line monotherapy (ambrisentan or tadalafil) in subjects with Pulmonary Arterial Hypertension. This will be assessed by time to the first clinical failure event.","primaryOutcome":{"measure":"Number of Participants With First Adjudicated Clinical Failure (CF) Event, Death, Hospitalisation for Worsening PAH, Disease Progression, Unsatisfactory Long-term Clinical Response, All Through FAV","timeFrame":"From Baseline up to the Final Assessment Visit (FAV) (average of 609 days)","effectByArm":[{"arm":"Combination Therapy: Ambrisentan + Tadalafil","deltaMin":46,"sd":null},{"arm":"Monotherapy Pooled: Ambrisentan or Tadalafil","deltaMin":77,"sd":null},{"arm":"Ambrisentan Monotherapy","deltaMin":43,"sd":null},{"arm":"Tadalafil Monotherapy","deltaMin":34,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0002"},{"comp":"OG000 vs OG002","p":"0.0004"},{"comp":"OG000 vs OG003","p":"0.0045"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":143,"countries":["United States","Australia","Austria","Belgium","Canada","France","Germany","Greece","Italy","Japan","Netherlands","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["32161055","31511080","28039187","26308684","26196225"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":124,"n":302},"commonTop":["Oedema peripheral","Headache","Diarrhoea","Dizziness","Nasopharyngitis"]}}